Literature DB >> 28698186

Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer.

Ilona Argirion1, Stephanie J Weinstein2, Satu Männistö3, Demetrius Albanes2, Alison M Mondul4.   

Abstract

Background: Although insulin may increase the risk of some cancers, few studies have examined fasting serum insulin and lung cancer risk.
Methods: We examined serum insulin, glucose, and indices of insulin resistance [insulin:glucose molar ratio and homeostasis model assessment of insulin resistance (HOMA-IR)] and lung cancer risk using a case-cohort study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish men. A total of 196 cases and 395 subcohort members were included. Insulin and glucose were measured in fasting serum collected 5 to 12 years before diagnosis. Cox proportional hazards models were utilized to estimate the relative risk of lung cancer.
Results: The average time between blood collection and lung cancer was 9.6 years. Fasting serum insulin levels were 8.7% higher in subcohort members than cases. After multivariable adjustment, men in the fourth quartile of insulin had a significantly higher risk of lung cancer than those in the first quartile [HR = 2.10; 95% confidence interval (CI), 1.12-3.94]. A similar relationship was seen with HOMA-IR (HR = 1.83; 95% CI, 0.99-3.38). Risk was not strongly associated with glucose or the insulin:glucose molar ratio (Ptrend = 0.55 and Ptrend = 0.27, respectively).Conclusions: Higher fasting serum insulin concentrations, as well as the presence of insulin resistance, appear to be associated with an elevated risk of lung cancer development.Impact: Although insulin is hypothesized to increase risk of some cancers, insulin and lung cancer remain understudied. Higher insulin levels and insulin resistance were associated with increased lung cancer risk. Although smoking cessation is the best method of lung cancer prevention, other lifestyle changes that affect insulin concentrations and sensitivity may reduce lung cancer risk. Cancer Epidemiol Biomarkers Prev; 26(10); 1519-24. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28698186      PMCID: PMC5626607          DOI: 10.1158/1055-9965.EPI-17-0293

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Prostate cancer risk and serum levels of insulin and leptin: a population-based study.

Authors:  A W Hsing; S Chua; Y T Gao; E Gentzschein; L Chang; J Deng; F Z Stanczyk
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk.

Authors:  Jiyoung Ahn; Stephanie J Weinstein; Kirk Snyder; Michael N Pollak; Jarmo Virtamo; Demetrius Albanes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

4.  A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.

Authors:  Veronica Vella; Giuseppe Pandini; Laura Sciacca; Rossana Mineo; Riccardo Vigneri; Vincenzo Pezzino; Antonino Belfiore
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

5.  Insulin resistance: an independent risk factor for lung cancer?

Authors:  Eleni Th Petridou; Theodoros N Sergentanis; Constantine N Antonopoulos; Nick Dessypris; Ioannis L Matsoukis; Konstantinos Aronis; Anna Efremidis; Constantinos Syrigos; Christos S Mantzoros
Journal:  Metabolism       Date:  2011-01-19       Impact factor: 8.694

6.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

Authors:  Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Yolanda Madarnas; Warren Hartwick; Barry Hoffman; Nicky Hood
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

Review 7.  Pathophysiology of insulin resistance.

Authors:  Giorgio Sesti
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2006-12       Impact factor: 4.690

8.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

Review 9.  PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?

Authors:  M A Lawlor; D R Alessi
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

10.  Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.

Authors:  S Lehrer; E J Diamond; S Stagger; N N Stone; R G Stock
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

View more
  15 in total

1.  Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative.

Authors:  Kathy Pan; Rebecca A Nelson; Jean Wactawski-Wende; Delphine J Lee; JoAnn E Manson; Aaron K Aragaki; Joanne E Mortimer; Lawrence S Phillips; Thomas Rohan; Gloria Y F Ho; Nazmus Saquib; Aladdin H Shadyab; Rami Nassir; Jinnie J Rhee; Arti Hurria; Rowan T Chlebowski
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

2.  Unrestrained eating behavior and risk of mortality: A prospective cohort study.

Authors:  Yin Zhang; Mingyang Song; Chen Yuan; Andrew T Chan; Eva S Schernhammer; Brian M Wolpin; Meir J Stampfer; Jeffrey A Meyerhardt; Charles S Fuchs; Susan B Roberts; Eric B Rimm; Walter C Willett; Frank B Hu; Edward L Giovannucci; Kimmie Ng
Journal:  Clin Nutr       Date:  2021-09-17       Impact factor: 7.324

3.  Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells.

Authors:  Marta Osrodek; Michal Rozanski; Malgorzata Czyz
Journal:  Cancer Manag Res       Date:  2020-08-13       Impact factor: 3.989

4.  Association Between Triglyceride Glucose Index and Non-Small Cell Lung Cancer Risk in Chinese Population.

Authors:  Xin Yan; Yujuan Gao; Jingzhi Tong; Mi Tian; Jinghong Dai; Yi Zhuang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

Review 5.  Morbid Obesity and Thyroid Cancer Rate. A Review of Literature.

Authors:  Stefania Masone; Nunzio Velotti; Silvia Savastano; Emanuele Filice; Rossana Serao; Antonio Vitiello; Giovanna Berardi; Vincenzo Schiavone; Mario Musella
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

Review 6.  Carbohydrate Nutrition and the Risk of Cancer.

Authors:  Christian A Maino Vieytes; Hania M Taha; Amirah A Burton-Obanla; Katherine G Douglas; Anna E Arthur
Journal:  Curr Nutr Rep       Date:  2019-09

7.  Assessing the association of diabetes with lung cancer risk.

Authors:  Amanda Leiter; Antonios Charokopos; Stacyann Bailey; Emily J Gallagher; Fred R Hirsch; Derek LeRoith; Juan P Wisnivesky
Journal:  Transl Lung Cancer Res       Date:  2021-11

8.  Triglyceride-Glucose Index Is Not Associated With Lung Cancer Risk: A Prospective Cohort Study in the UK Biobank.

Authors:  Lijie Wang; Shucheng Si; Jiqing Li; Yunxia Li; Xiaolu Chen; Fuzhong Xue; Wangang Ren
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 5.738

9.  Mitochondrial Dynamics Related Genes -MFN1, MFN2 and DRP1 Polymorphisms are Associated with Risk of Lung Cancer.

Authors:  Xiaohua Liang; Shengqiang Dang
Journal:  Pharmgenomics Pers Med       Date:  2021-06-14

10.  Insulin reverses choriocarcinoma 5- fluorouracil resistance.

Authors:  Ying Shan; Yanyi Li; Hongyu Han; Cui Jiang; Hu Zhang; Jiachang Hu; Huanmei Sun; Jianglong Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.